mitoxantrone has been researched along with Diffuse Large B-Cell Lymphoma in 44 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied." | 9.10 | Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas. ( Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K, 2002) |
| " We present the results of systemic treatment using rituximab plus dose reduced mitoxantrone, cyclophosphamide, vincristine, and prednisolone in three elderly patients with primary diffuse large B-cell lymphoma (DLBCL) of the thyroid." | 7.76 | Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid. ( Hoffmann, M; Jonak, C; Müllauer, L; Niederle, B; Raderer, M; Troch, M, 2010) |
| " Two toxic deaths were observed." | 6.78 | High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. ( Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013) |
| "Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied." | 5.10 | Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas. ( Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K, 2002) |
| "The prognosis of diffuse large B-cell lymphoma (DLBCL) has improved significantly since the introduction of immunochemotherapy (rituximab [R] with cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP])." | 3.78 | Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. ( Andersson, PO; Hansson, U; Hasselblom, S; Lewerin, C; Nilsson-Ehle, H; Sender, M; Stenson, M; Werlenius, O, 2012) |
| " We present the results of systemic treatment using rituximab plus dose reduced mitoxantrone, cyclophosphamide, vincristine, and prednisolone in three elderly patients with primary diffuse large B-cell lymphoma (DLBCL) of the thyroid." | 3.76 | Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid. ( Hoffmann, M; Jonak, C; Müllauer, L; Niederle, B; Raderer, M; Troch, M, 2010) |
| " Two toxic deaths were observed." | 2.78 | High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. ( Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013) |
| "Pixantrone is a first-in-class aza-anthracenedione approved as monotherapy for treatment of relapsed or refractory aggressive diffuse B-cell non-Hodgkin's lymphoma (NHL), a patient group which is notoriously difficult to treat." | 2.58 | Pixantrone: novel mode of action and clinical readouts. ( Bertoni, F; Cattan, V; Egorov, A; Han, H; Minotti, G, 2018) |
| "Histopathological subtypes consist of Burkitt's lymphoma (BL) in 32 (43." | 1.48 | Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan. ( Anwar, S; Faizan, M; Khan, S, 2018) |
| "Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course." | 1.32 | A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. ( Aoun, P; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Greiner, TC; Hans, CP; Hock, LM; Lynch, JC; Vose, JM; Weisenburger, DD, 2003) |
| "Lymphoma is an unusual cause of tracheoesophageal fistula (TEF)." | 1.29 | Tracheoesophageal fistula developing during chemotherapy for non-Hodgkins lymphoma. ( Bierman, PJ; Galbraith, TA; Lackner, RP, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.27) | 18.7374 |
| 1990's | 9 (20.45) | 18.2507 |
| 2000's | 23 (52.27) | 29.6817 |
| 2010's | 9 (20.45) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Lombion, N | 1 |
| Robin, P | 1 |
| Tempescul, A | 1 |
| LE Roux, PY | 1 |
| Schick, U | 1 |
| Guillerm, G | 1 |
| Ianotto, JC | 1 |
| Berthou, C | 1 |
| Salaün, PY | 1 |
| Abgral, R | 1 |
| Yang, X | 1 |
| Wang, Y | 2 |
| Sun, X | 1 |
| Bai, X | 1 |
| Cui, Q | 1 |
| Zhu, H | 1 |
| Qian, J | 1 |
| Chen, Y | 2 |
| Sun, S | 1 |
| Ji, N | 1 |
| Liu, Y | 2 |
| Faizan, M | 1 |
| Anwar, S | 1 |
| Khan, S | 1 |
| Minotti, G | 1 |
| Han, H | 1 |
| Cattan, V | 1 |
| Egorov, A | 1 |
| Bertoni, F | 1 |
| Gyan, E | 1 |
| Damotte, D | 1 |
| Courby, S | 1 |
| Sénécal, D | 1 |
| Quittet, P | 1 |
| Schmidt-Tanguy, A | 1 |
| Banos, A | 1 |
| Le Gouill, S | 1 |
| Lamy, T | 1 |
| Fontan, J | 1 |
| Maisonneuve, H | 1 |
| Alexis, M | 1 |
| Dreyfus, F | 1 |
| Tournilhac, O | 1 |
| Laribi, K | 1 |
| Solal-Céligny, P | 1 |
| Arakelyan, N | 1 |
| Cartron, G | 1 |
| Gressin, R | 1 |
| Lowry, L | 1 |
| Smith, P | 1 |
| Cunningham, D | 1 |
| Linch, DC | 1 |
| Amorim, S | 1 |
| Fleury, I | 1 |
| Mounier, N | 1 |
| Harel, S | 1 |
| Brice, P | 1 |
| Thieblemont, C | 1 |
| Miao, X | 1 |
| Wu, Y | 1 |
| Zhu, X | 1 |
| Yin, H | 1 |
| He, Y | 1 |
| Li, C | 1 |
| Lu, X | 1 |
| Shen, R | 1 |
| Xu, X | 1 |
| He, S | 1 |
| Fu, K | 1 |
| Weisenburger, DD | 2 |
| Choi, WW | 1 |
| Perry, KD | 1 |
| Smith, LM | 1 |
| Shi, X | 1 |
| Hans, CP | 2 |
| Greiner, TC | 2 |
| Bierman, PJ | 3 |
| Bociek, RG | 2 |
| Armitage, JO | 3 |
| Chan, WC | 2 |
| Vose, JM | 2 |
| Held, G | 1 |
| Pfreundschuh, M | 1 |
| Sieniawski, M | 1 |
| Bhartia, S | 1 |
| Wilkinson, J | 1 |
| Proctor, SJ | 1 |
| Jonak, C | 1 |
| Troch, M | 1 |
| Müllauer, L | 1 |
| Niederle, B | 1 |
| Hoffmann, M | 1 |
| Raderer, M | 1 |
| Hasselblom, S | 1 |
| Stenson, M | 1 |
| Werlenius, O | 1 |
| Sender, M | 1 |
| Lewerin, C | 1 |
| Hansson, U | 1 |
| Nilsson-Ehle, H | 1 |
| Andersson, PO | 1 |
| Giachelia, M | 1 |
| Voso, MT | 1 |
| Tisi, MC | 1 |
| Martini, M | 1 |
| Bozzoli, V | 1 |
| Massini, G | 1 |
| D'Aló, F | 1 |
| Larocca, LM | 1 |
| Leone, G | 1 |
| Hohaus, S | 1 |
| Hock, LM | 1 |
| Lynch, JC | 1 |
| Aoun, P | 1 |
| Rigacci, L | 1 |
| Carpaneto, A | 1 |
| Alterini, R | 1 |
| Carrai, V | 1 |
| Bernardi, F | 1 |
| Bellesi, G | 1 |
| Longo, G | 1 |
| Bosi, A | 1 |
| Rossi Ferrini, P | 1 |
| Barutca, S | 1 |
| Kadikoylu, G | 1 |
| Bolaman, Z | 1 |
| Levi, E | 1 |
| Yavasoglu, I | 1 |
| Zinzani, PL | 2 |
| Stefoni, V | 2 |
| Alinari, L | 2 |
| Vianelli, N | 1 |
| Baccarani, M | 2 |
| Froehner, M | 1 |
| Haase, M | 1 |
| Hakenberg, OW | 1 |
| Wirth, MP | 1 |
| Hendry, L | 1 |
| Bowen, A | 1 |
| Matutes, E | 1 |
| Swansbury, J | 1 |
| Catovsky, D | 1 |
| Vitolo, U | 2 |
| Liberati, AM | 2 |
| Cabras, MG | 1 |
| Federico, M | 1 |
| Angelucci, E | 1 |
| Baldini, L | 1 |
| Boccomini, C | 1 |
| Brugiatelli, M | 1 |
| Calvi, R | 2 |
| Ciccone, G | 1 |
| Genua, A | 1 |
| Deliliers, GL | 1 |
| Levis, A | 2 |
| Parvis, G | 1 |
| Pavone, E | 1 |
| Salvi, F | 1 |
| Sborgia, M | 1 |
| Gallo, E | 1 |
| Otrock, ZK | 1 |
| Shamseddine, AI | 1 |
| Taher, AT | 1 |
| Hazlehurst, LA | 1 |
| Argilagos, RF | 1 |
| Emmons, M | 1 |
| Boulware, D | 1 |
| Beam, CA | 1 |
| Sullivan, DM | 1 |
| Dalton, WS | 1 |
| Yokoyama, M | 1 |
| Kobayashi, T | 1 |
| Kubo, Y | 1 |
| Kageyama, Y | 1 |
| Kihara, K | 1 |
| Niitsu, N | 1 |
| Kohuri, M | 1 |
| Higashihara, M | 1 |
| Bessho, M | 2 |
| Sugimoto, T | 1 |
| Matano, S | 1 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 1 |
| Munemoto, S | 1 |
| Satoh, S | 1 |
| Tse, E | 1 |
| Chan, JC | 1 |
| Pang, A | 1 |
| Au, WY | 1 |
| Leung, AY | 1 |
| Lam, CC | 1 |
| Kwong, YL | 1 |
| Tarella, C | 1 |
| Zanni, M | 1 |
| Di Nicola, M | 1 |
| Patti, C | 1 |
| Pescarollo, A | 1 |
| Zoli, V | 1 |
| Fornari, A | 1 |
| Novero, D | 1 |
| Cabras, A | 1 |
| Stella, M | 1 |
| Comino, A | 1 |
| Remotti, D | 1 |
| Ponzoni, M | 1 |
| Caracciolo, D | 1 |
| Ladetto, M | 1 |
| Magni, M | 1 |
| Devizzi, L | 1 |
| Rosato, R | 1 |
| Boccadoro, M | 1 |
| Bregni, M | 1 |
| Corradini, P | 1 |
| Gallamini, A | 1 |
| Majolino, I | 1 |
| Mirto, S | 1 |
| Gianni, AM | 1 |
| Humeniuk, R | 1 |
| Menon, LG | 1 |
| Mishra, PJ | 1 |
| Saydam, G | 1 |
| Longo-Sorbello, GS | 1 |
| Elisseyeff, Y | 1 |
| Lewis, LD | 1 |
| Aracil, M | 1 |
| Jimeno, J | 1 |
| Bertino, JR | 1 |
| Banerjee, D | 1 |
| Fina, M | 1 |
| Tani, M | 1 |
| Musuraca, G | 1 |
| Marchi, E | 1 |
| Pellegrini, C | 1 |
| Derenzini, E | 1 |
| Bacci, F | 1 |
| Pileri, S | 1 |
| Roboz, J | 1 |
| Paciucci, PA | 1 |
| Silides, D | 1 |
| Greaves, J | 1 |
| Holland, JF | 1 |
| Avilés, A | 1 |
| Díaz-Maqueo, JC | 1 |
| Talavera, A | 1 |
| Nambo, MJ | 1 |
| García, EL | 1 |
| Cortes, JE | 1 |
| Talpaz, M | 1 |
| Cabanillas, F | 1 |
| Seymour, JF | 1 |
| Kurzrock, R | 1 |
| Ohnoshi, T | 1 |
| Hayashi, K | 1 |
| Ueno, K | 1 |
| Tada, A | 1 |
| Mizuta, J | 1 |
| Tagawa, S | 1 |
| Matsutomo, S | 1 |
| Saito, S | 1 |
| Kawashima, K | 1 |
| Yoshino, T | 1 |
| Lackner, RP | 1 |
| Galbraith, TA | 1 |
| Cortellazzo, S | 1 |
| Freilone, R | 1 |
| Falda, M | 1 |
| Bertini, M | 1 |
| Botto, B | 1 |
| Cinieri, S | 1 |
| Locatelli, F | 1 |
| Lovisone, E | 1 |
| Marmont, F | 1 |
| Pizzuti, M | 1 |
| Rossi, A | 1 |
| Viero, P | 1 |
| Barbui, T | 1 |
| Grignani, F | 1 |
| Resegotti, L | 1 |
| Satoh, T | 1 |
| Tsushima, K | 1 |
| Hizawa, Y | 1 |
| Nakui, Y | 1 |
| Itoh, J | 1 |
| Tamura, Y | 1 |
| Saitoh, S | 1 |
| Taka-mi, H | 1 |
| Munakata, A | 1 |
| Kawamura, S | 1 |
| Inatomi, Y | 1 |
| Inoue, T | 1 |
| Nagata, S | 1 |
| Matsuno, H | 1 |
| Itoh, Y | 2 |
| Orlandi, E | 1 |
| Lazzarino, M | 1 |
| Bernasconi, P | 1 |
| Astori, C | 1 |
| Bernasconi, C | 1 |
| Ruiz Hernández, G | 1 |
| Pallardó-Calatayud, J | 1 |
| Ferrer Albiach, C | 1 |
| Balaguer-Martínez, JV | 1 |
| Romero-de-Avila, C | 1 |
| Castillo-Pallarés, FJ | 1 |
| Tsirigotis, P | 1 |
| Economopoulos, T | 1 |
| Rontogianni, D | 1 |
| Dervenoulas, J | 1 |
| Papageorgiou, E | 1 |
| Bollas, G | 1 |
| Mantzios, G | 1 |
| Kalantzis, D | 1 |
| Koumarianou, A | 1 |
| Raptis, S | 1 |
| Murohashi, I | 1 |
| Kashimura, T | 1 |
| Tominaga, K | 1 |
| Wakao, D | 1 |
| Takahashi, T | 1 |
| Akiba, M | 1 |
| Kishimoto, K | 1 |
| Yoshida, K | 1 |
| Yagasaki, F | 1 |
| Sakata, T | 1 |
| Kawai, N | 1 |
| Itoh, K | 1 |
| Suzuki, T | 1 |
| Matsuda, A | 1 |
| Hirashima, K | 1 |
| Itoh, T | 1 |
| Sakata, Y | 1 |
| Suzuki, H | 1 |
| Sugimoto, N | 1 |
| Sohma, N | 1 |
| Kishibe, T | 1 |
| Higuchi, S | 1 |
| Seino, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883] | Phase 1 | 9 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588] | Phase 1 | 4 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell[NCT02916316] | 127 participants (Actual) | Observational | 2014-02-12 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for mitoxantrone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Pixantrone: novel mode of action and clinical readouts.
Topics: Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Humans; Isoquinolines; Lymphoma, Large | 2018 |
Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etopo | 2003 |
Trigeminal neuralgia caused by the metastasis of malignant lymphoma to the trigeminal nerve: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cranial Nerve Neopl | 1998 |
The role of mitoxantrone in non-Hodgkin's lymphoma.
Topics: Age Factors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2002 |
7 trials available for mitoxantrone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosp | 2005 |
Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2006 |
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Dise | 1994 |
Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamid | 2002 |
33 other studies available for mitoxantrone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Fluoro | 2021 |
STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2020 |
Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2018 |
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau | 2013 |
Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2016 |
Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma.
Topics: Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; | 2016 |
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Hematology: germinal center or nongerminal center DLBCL?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Germinal Center; Huma | 2009 |
Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2010 |
Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2012 |
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2003 |
Non-Hodgkin's lymphoma presenting as a giant chest wall mass.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; | 2003 |
Urinary immunocytology for primary bladder B cell lymphoma.
Topics: Aged; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocy | 2004 |
Non-Hodgkin disease in beta-thalassemia major.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta-Thalassemia; Child; Child, Preschool; Co | 2006 |
Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
Topics: Cell Adhesion; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Fanconi Anemia Co | 2006 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2006 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia | 2007 |
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italian
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2007 |
Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2007 |
Detection and quantification of mitoxantrone in human organs. A case report.
Topics: Aged; Anthraquinones; Antineoplastic Agents; Autopsy; Chromatography, High Pressure Liquid; Humans; | 1984 |
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin | 1995 |
Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: a single-institutional study with a long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1993 |
Tracheoesophageal fistula developing during chemotherapy for non-Hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, Large B-C | 1996 |
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 1997 |
[Combination chemotherapy with BH-AC, mitoxantrone, etoposide, and prednisolone to refractory or relapsed malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedul | 1997 |
Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1998 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combi | 2001 |
T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
Topics: Aged; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2001 |
[A case of diffuse large cell lymphoma treated with combination chemotherapy of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and BEMP (bleomycin, etoposide, mitoxantrone, procarbazine) with complete remission].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophospham | 1992 |